Clinical Trial Update: Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing efficacy, safety, and immunogenicity of AVT02 in moderate-to-severe chronic plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• AVT02 (adalimumab biosimilar)

Snippet

Sponsor: Alvotech Swiss AG | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED